Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11717665 | 0.87 | IDO1 (0.38) | PNMTTAAR1IDO1KDM4E | |
| SCHEMBL15247 | 0.79 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| SCHEMBL29405036 | 0.79 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| SCHEMBL8506507 | 0.76 | IDO1 (0.32) | IDO1 | |
| SCHEMBL8830195 | 0.76 | FDPS (0.50) | TAAR1IDO1SMN1; SMN2 | |
| SCHEMBL22969779 | 0.76 | GABRA1 (0.46) | — | |
| SCHEMBL396630 | 0.76 | RIPK1 (0.47) | PNMTDPP4TAAR1LOXL2 | |
| SCHEMBL7847384 | 0.76 | TRPA1 (0.35) | IDO1 | |
| Benzene SCHEMBL734438 | 0.76 | DPP4 (0.62) | PNMTDPP4TAAR1LOXL2CYP2A6 | |
| Water SCHEMBL7618285 | 0.76 | PNMT (0.60) | PNMTDPP4TAAR1LOXL2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| EP-1556373-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035566-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | PNMT 603/4885DPP4 3943/4885TAAR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.